Study shows elderly black, Hispanic diabetes patients have greater risk of losing eyesight
NEW YORK Elderly blacks and Hispanics face the greatest risk of losing their vision due to diabetes over the next 40 years, according to a new study by the Centers for Disease Control and Prevention published in The Archives of Ophthalmology.
The disproportionate numbers among them results from higher instances of Type 2, or adult-onset diabetes. In 2005, 5.5 million adults aged 40 and older in the United States had diabetes-related blindness, also known as diabetic retinopathy; in 2050, according to the report, that number could reach 16 million.
In addition to diabetic retinopathy, diabetes also increases the risk of cataracts and glaucoma, and the incidence of glaucoma will increase 12 times among Hispanics with diabetes aged 65 and older; among blacks with diabetes aged 75 and older, the incidence of cataracts will increase 7 times.
FDA approves Galderma’s Epiduo Gel treatment for acne
ROCKVILLE, Md. The Food and Drug Administration has approved a new acne treatment by Galderma Laboratories, the agency announced Wednesday.
The treatment, Epiduo Gel, is known generically as adapalene and benzoyl peroxide and is used to treat acne vulgaris in patients aged 12 and older.
FDA records indicate the agency approved it Monday.
Galderma, based in Lausanne, Switzerland, had not made a statement about the approval at midday Wednesday.
Wyeth announces lay-offs at operations in Puerto Rico
SAN JUAN, Puerto Rico More than 200 Wyeth Pharmaceuticals employees in Puerto Rico will lose their jobs between the end of the year and February, according to the Associated Press.
The drug maker said it would lay off 276 workers as part of a restructuring plan and drop in demand. The company employs about 3,000 people in the territory.
A spokeswoman for the company said the availability of generics reduced demand for the anti-anxiety drug Effexor (venlafaxine hydrochloride) and the acid reflux disease drug Protonix (pantoprazole sodium).